Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517868 · ClinicalTrials.gov registry record · Phase 2
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A Phase 2 study, sponsored by Urigen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00517868: Clinical Trial Phase 2 study, sponsored by Urigen.
NCT00517868 is a Phase 2 study that was terminated before completion, run by Urigen. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00517868, a Phase 2 study, was terminated before completion, sponsored by Urigen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
Primary Outcome
A calculation of average bladder pain intensity differences from baseline to 12 hours post-dose , as determined using an 11-point numerical rating scale (NRS) for bladder pain from time of dosing through 12 hours post dose. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Interventions
- DRUG Placebo
- DRUG URG101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-08-28 |
| Est. Completion | 2008-02-28 |
| Phase | Phase 2 |
Why NCT00517868 stopped before completion
NCT00517868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00517868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00517868 about?
NCT00517868 is a clinical study titled "Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis". A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
What is the current status of trial NCT00517868?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-08-28. Estimated completion is 2008-02-28.
What interventions are being tested in trial NCT00517868?
The interventions under investigation include: Placebo (DRUG), URG101 (DRUG).
Who is sponsoring clinical trial NCT00517868?
This trial is sponsored by Urigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00517868's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI